Is Context Therapeutics Inc. Common Stock a good investment? Context Therapeutics Inc. Common Stock (CNTX) is currently trading at 0.1808 USD. Market analysts have a consensus price target of 4.14 USD. This suggests a potential upside from current levels.
Earnings Schedule: Context Therapeutics Inc. Common Stock is expected to release its next earnings report on March 22, 2027. The market consensus estimate for Forward EPS is -0.42.
No, it does not currently pay a dividend.
Context Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be March 22, 2027. The company currently has a trailing EPS of -0.46.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Community Discussion